Harvard Business Review September 4, 2024
David Blumenthal, Bakul Patel

Summary: A challenge confronting the Food and Drug Administration — and other regulators around the world — is how to regulate generative AI. The approach it uses for new drugs and devices isn’t appropriate. Instead, the FDA should be conceiving of LLMs as novel forms of intelligence. It should employ similar approaches to those it applies to clinicians.

Generative AI has arrived in medicine. Normally, when a new device or drug enters the U.S. market, the Food and Drug Administration (FDA) reviews it for safety...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Govt Agencies, Regulations, Technology
Managed Care History Part III: The Rise of Machine-Driven Managed Care
Building Solutions To Turn Pain Points Into Opportunities In The Era Of AI
AI In R&D: Augmenting Scientific Discovery
Meta’s new BLT architecture replaces tokens to make LLMs more efficient and versatile
Johns Hopkins Medicine inks AI deal with Abridge

Share This Article